BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22460241)

  • 1. Adverse cardiovascular outcomes associated with concurrent use of clopidogrel or ticlopidine and proton-pump inhibitors in patients undergoing percutaneous coronary intervention.
    Nakayama A; Morita H; Ando J; Fujita H; Ohtsu H; Nagai R
    Heart Vessels; 2013 May; 28(3):292-300. PubMed ID: 22460241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012 - 2016).
    Bundhun PK; Teeluck AR; Bhurtu A; Huang WQ
    BMC Cardiovasc Disord; 2017 Jan; 17(1):3. PubMed ID: 28056809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study.
    Ray WA; Murray KT; Griffin MR; Chung CP; Smalley WE; Hall K; Daugherty JR; Kaltenbach LA; Stein CM
    Ann Intern Med; 2010 Mar; 152(6):337-45. PubMed ID: 20231564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
    Chandrasekhar J; Bansilal S; Baber U; Sartori S; Aquino M; Farhan S; Vogel B; Faggioni M; Giustino G; Ariti C; Colombo A; Chieffo A; Kini A; Saporito R; Michael Gibson C; Witzenbichler B; Cohen D; Moliterno D; Stuckey T; Henry T; Pocock S; Dangas G; Gabriel Steg P; Mehran R
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):E217-E225. PubMed ID: 27650638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry.
    Aihara H; Sato A; Takeyasu N; Nishina H; Hoshi T; Akiyama D; Kakefuda Y; Watabe H; Aonuma K;
    Catheter Cardiovasc Interv; 2012 Oct; 80(4):556-63. PubMed ID: 22234956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome.
    Bhurke SM; Martin BC; Li C; Franks AM; Bursac Z; Said Q
    Pharmacotherapy; 2012 Sep; 32(9):809-18. PubMed ID: 22744772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials.
    Dunn SP; Steinhubl SR; Bauer D; Charnigo RJ; Berger PB; Topol EJ
    J Am Heart Assoc; 2013 Jan; 2(1):e004564. PubMed ID: 23525436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of the clopidogrel-proton pump inhibitor interaction after peripheral endovascular intervention for claudication.
    Meltzer AJ; Da Silva P; Schneider DB; Shrikhande GV
    Vasc Endovascular Surg; 2012 Oct; 46(7):524-9. PubMed ID: 22989428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial.
    Burkard T; Kaiser CA; Brunner-La Rocca H; Osswald S; Pfisterer ME; Jeger RV;
    J Intern Med; 2012 Mar; 271(3):257-63. PubMed ID: 21726302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation.
    Schmidt M; Johansen MB; Robertson DJ; Maeng M; Kaltoft A; Jensen LO; Tilsted HH; Bøtker HE; Sørensen HT; Baron JA
    Aliment Pharmacol Ther; 2012 Jan; 35(1):165-74. PubMed ID: 22050009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention.
    Gupta E; Bansal D; Sotos J; Olden K
    Dig Dis Sci; 2010 Jul; 55(7):1964-8. PubMed ID: 19731021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton Pump Inhibitor and Clopidogrel Use After Percutaneous Coronary Intervention and Risk of Major Cardiovascular Events.
    Maret-Ouda J; Santoni G; Xie S; Rosengren A; Lagergren J
    Cardiovasc Drugs Ther; 2022 Dec; 36(6):1121-1128. PubMed ID: 34241731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.
    O'Donoghue ML; Braunwald E; Antman EM; Murphy SA; Bates ER; Rozenman Y; Michelson AD; Hautvast RW; Ver Lee PN; Close SL; Shen L; Mega JL; Sabatine MS; Wiviott SD
    Lancet; 2009 Sep; 374(9694):989-997. PubMed ID: 19726078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.
    Tentzeris I; Jarai R; Farhan S; Brozovic I; Smetana P; Geppert A; Wojta J; Siller-Matula J; Huber K
    Thromb Haemost; 2010 Dec; 104(6):1211-8. PubMed ID: 20941464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome.
    Rassen JA; Choudhry NK; Avorn J; Schneeweiss S
    Circulation; 2009 Dec; 120(23):2322-9. PubMed ID: 19933932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study.
    Jackson LR; Peterson ED; McCoy LA; Ju C; Zettler M; Baker BA; Messenger JC; Faries DE; Effron MB; Cohen DJ; Wang TY
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major adverse cardiac events among postpercutaneous coronary intervention patients on clopidogrel and proton pump inhibitors.
    Ching GG; Li D; Baker WL; Hohl PK; Mather JF; McKay RG; Lundbye JB
    Conn Med; 2012 Apr; 76(4):205-11. PubMed ID: 22611719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding.
    Tsai YW; Wen YW; Huang WF; Chen PF; Kuo KN; Hsiao FY
    J Gastroenterol; 2011 Jan; 46(1):39-45. PubMed ID: 20811753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis.
    Serbin MA; Guzauskas GF; Veenstra DL
    J Manag Care Spec Pharm; 2016 Aug; 22(8):939-47. PubMed ID: 27459657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study.
    Charlot M; Ahlehoff O; Norgaard ML; Jørgensen CH; Sørensen R; Abildstrøm SZ; Hansen PR; Madsen JK; Køber L; Torp-Pedersen C; Gislason G
    Ann Intern Med; 2010 Sep; 153(6):378-86. PubMed ID: 20855802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.